Obesity is a global health crisis affecting over 2.3 billion individuals worldwide. This prospective study aims to evaluate the comparative effects of standardised Cissus quadrangularis extract (CQE) and Dichrostachys glomerata extract (DGE) on obesity-related parameters, focusing on their impact on glucagon-like peptide-1 (GLP-1) levels and dipeptidyl peptidase-4 (DPP-4) enzyme activity in obese subjects. Parameters such as GLP-1 levels, DPP-4 activity, food intake, satiety, body weight, blood lipids, fasting blood glucose, and visceral fat mass will be measured at baseline and various intervals. In our previous pre-clinical trial involving 18 adult male Wistar rats (150-200 g), randomly divided into three groups: a control group fed a normal diet, and two treatment groups receiving DGE (400 mg/kg) or CQE (300 mg/kg) alongside a normal diet, the results demonstrated that both DGE and CQE significantly increased GLP-1 levels and inhibited DPP-4 activity compared to the control group. These effects were associated with reduced food intake, body weight, and fasting blood glucose levels. Additionally, both extracts positively modified blood lipid profiles, with significant changes in HDL, LDL, and triglyceride levels. The findings suggest that DGE and CQE exert their anti-obesity effects through mechanisms involving GLP-1 enhancement and DPP-4 inhibition, offering potential therapeutic pathways for weight management and metabolic health. This prospective study aims to provide clinical evidence supporting the use of these plant extracts in addressing obesity and its related complications.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Effect of Dyglomera® and CQR-300® on participants GLP-1 level
Timeframe: Baseline (Week 0), Week 4, Week 8, and Week 12
Effect of Dyglomera® and CQR-300® on participants BMI
Timeframe: Baseline (Week 0), Week 4, Week 8, and Week 12
Effect of Dyglomera® and CQR-300® on participants Fasting blood glucose
Timeframe: Baseline (Week 0), Week 4, Week 8, and Week 12
Effect of Dyglomera® and CQR-300® on participants DPP4 activity
Timeframe: Baseline (Week 0), Week 4, Week 8, and Week 12
Effect of Dyglomera® and CQR-300® on participants Lipid Profile
Timeframe: Baseline (Week 0), Week 4, Week 8, and Week 12
Effect of Dyglomera® and CQR-300® on participants Body Fat percentage
Timeframe: Baseline (Week 0), Week 4, Week 8, and Week 12
Effect of Dyglomera® and CQR-300® on participants Body weight
Timeframe: Baseline (Week 0), Week 4, Week 8, and Week 12